Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target.

X Fan1, J Xie1, J Tian1

  • 1Department of Medicine, Center for Hypertension and Personalized Medicine, University of Toledo, Ohio 43614, USA.

Cardiovascular Pharmacology: Open Access
|October 17, 2017
PubMed
Summary

Cardiac fibrosis, a key factor in heart failure, can be targeted by blocking Na/K-ATPase signaling. Novel therapeutic strategies focus on the Na/K-ATPase signaling complex to reduce cardiac fibrosis and improve heart function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Properties of Heavy Cosmic Nuclei Phosphorus, Chlorine, Argon, Potassium, and Calcium: Results from the Alpha Magnetic Spectrometer.

Physical review letters·2026
Same author

[Analysis of hospital associated infection characteristics in pediatric patients undergoing hematopoietic stem cell transplantation].

Zhonghua yi xue za zhi·2026
Same author

Withdrawal notice to "Relationship between coronary microvascular dysfunction (CMD) and left ventricular diastolic function in patients with symptoms of myocardial ischemia with non-obstructive coronary artery disease (INOCA) by cardiovascular magnetic resonance feature-tracking"[ClinRad 79(7) (July 2024) 536-543.

Clinical radiology·2026
Same author

[Myeloproliferative neoplasm with a homozygous germline SH2B3 mutation: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2026
Same author

Obesity-driven thyroid cancer burden in middle-aged and older populations: temporal trends and projected trajectories based on the Global Burden of Disease study.

Hong Kong medical journal = Xianggang yi xue za zhi·2026
Same author

[Atypical Lemierre syndrome following blunt neck trauma: a case report].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2026

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Pathology

Background:

  • Cardiac fibrosis is a pathological process contributing to heart failure and sudden cardiac death.
  • It involves replacement fibrosis (scarring after injury) and reactive fibrosis (due to hormonal or pressure changes).
  • Established pathways like the Renin-Angiotensin-Aldosterone System (RAAS) are implicated, but heart failure remains a leading cause of death.

Purpose of the Study:

  • To review novel molecular targets for treating cardiac fibrosis.
  • To focus on the Na/K-ATPase signaling complex as a promising therapeutic target.
  • To discuss recent developments in blocking Na/K-ATPase signaling for fibrosis reduction.

Main Methods:

  • Review of experimental studies and clinical trials related to cardiac fibrosis pathways.
Keywords:
Cardia fibrosisNa/K-ATPaseSignalingTherapeutic target

Related Experiment Videos

  • Investigation of the role of Na/K-ATPase as both an ion transporter and signal transducer.
  • Analysis of novel tools developed to block Na/K-ATPase signaling.

    • Main Results:

    • Prolonged activation of Na/K-ATPase signaling promotes cardiac fibrosis formation.
    • Novel blockers of Na/K-ATPase signaling show promise in reducing cardiac fibrosis.
    • Despite advances, heart failure treatment requires new therapeutic targets.

    Conclusions:

    • The Na/K-ATPase signaling complex represents a novel and promising therapeutic target for cardiac fibrosis.
    • Targeting Na/K-ATPase signaling offers a potential strategy to combat heart failure.
    • Further development of Na/K-ATPase inhibitors could lead to improved treatments for cardiovascular disease.